Close Menu

NEW YORK (360Dx) – Private financing in the diagnostics space is on pace to decline year over year with tests for diagnosing cancers grabbing the lion's share of the funding.

Despite the drop off, though, moving forward, new, high-profile, non-traditional investors may be poised to shake up the investment landscape, one expert said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.